Knight Therapeutics Inc.

Informe acción TSX:GUD

Capitalización de mercado: CA$525.2m

Salud financiera de hoja de balance de Knight Therapeutics

Salud financiera controles de criterios 5/6

Knight Therapeutics tiene un patrimonio de accionistas total de CA$773.9M y una deuda total de CA$51.7M, lo que sitúa su ratio deuda-patrimonio en 6.7%. Sus activos y pasivos totales son CA$962.3M y CA$188.4M respectivamente. El BAIT de Knight Therapeutics es de CA$10.3M, por lo que su ratio de cobertura de intereses es de 277.7. Tiene efectivo e inversiones a corto plazo que ascienden a CA$172.3M.

Información clave

6.7%

Ratio deuda-patrimonio

CA$51.65m

Deuda

Ratio de cobertura de intereses277.7x
EfectivoCA$172.32m
PatrimonioCA$773.91m
Total pasivoCA$188.39m
Activos totalesCA$962.29m

Actualizaciones recientes sobre salud financiera

Recent updates

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 09
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$397.6M) de GUD superan a sus pasivos a corto plazo (CA$118.2M).

Pasivo a largo plazo: Los activos a corto plazo de GUD (CA$397.6M) superan a sus pasivos a largo plazo (CA$70.2M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: GUD tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de GUD ha crecido de 0% a 6.7% en los últimos 5 años.

Cobertura de la deuda: La deuda de GUD está bien cubierta por el flujo de caja operativo (102.1%).

Cobertura de intereses: Los pagos de intereses de la deuda de GUD están bien cubiertos por el BAIT (277.7x cobertura).


Hoja de balance


Descubre empresas con salud financiera